Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
Oncotarget
.
2017 Oct 25;8(55):93315-93316.
doi: 10.18632/oncotarget.22074.
eCollection 2017 Nov 7.
Authors
Timothy C Thompson
1
,
Likun Li
1
,
Bradley M Broom
1
Affiliation
1
Timothy C. Thompson: Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID:
29212150
PMCID:
PMC5706796
DOI:
10.18632/oncotarget.22074
No abstract available
Keywords:
PARP inhibitors; castration-resistant prostate cancer; combination therapy; enzalutamide.
Publication types
Editorial
Grants and funding
P50 CA140388/CA/NCI NIH HHS/United States